Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC

Launched by BETAGLUE THERAPEUTICS SPA ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people with a type of pancreatic cancer that cannot be removed by surgery. The treatment involves placing a small radioactive implant directly into the tumor in the pancreas, combined with standard chemotherapy. The main goals are to find out if this new approach is safe, if it can be done successfully, and how it affects patients’ quality of life, including pain levels. Doctors will also watch how the tumor responds to the treatment over a few months.

People aged 65 to 74 with locally advanced pancreatic cancer that cannot be surgically removed may be eligible to join. Participants will be involved in the study for about 7 months, during which they will receive regular chemotherapy alongside the new treatment. The implant is given in a single injection during a short hospital stay. Throughout the study, patients will visit the clinic multiple times for check-ups, scans, blood and urine tests, and to complete questionnaires about their well-being and pain. This study is not yet recruiting, but aims to offer important information about a possible new way to treat this challenging type of cancer.

Gender

ALL

Eligibility criteria